136 related articles for article (PubMed ID: 37355521)
1. EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery.
Fujiwara T; Shien K; Matsuura M; Soh J; Yamamoto H; Takao S; Maki Y; Ueno T; Sugimoto R; Suzawa K; Okazaki M; Tao H; Hayama M; Kataoka M; Sano Y; Inokawa H; Yamashita M; Kawamata O; Kataoka K; Toyooka S
Ann Surg Oncol; 2023 Oct; 30(11):6697-6702. PubMed ID: 37355521
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy.
Okamoto T; Iwata T; Mizobuchi T; Hoshino H; Moriya Y; Yoshida S; Yoshino I
Eur J Cardiothorac Surg; 2012 Jan; 41(1):25-30. PubMed ID: 21616674
[TBL] [Abstract][Full Text] [Related]
3. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
Song Z; Wang W; Li M; Liu J; Zhang Y
Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
[TBL] [Abstract][Full Text] [Related]
4. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
[TBL] [Abstract][Full Text] [Related]
5. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
[TBL] [Abstract][Full Text] [Related]
6. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
[TBL] [Abstract][Full Text] [Related]
7. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
[TBL] [Abstract][Full Text] [Related]
12. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
[TBL] [Abstract][Full Text] [Related]
13. EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors.
Yang J; Lee OJ; Son SM; Woo CG; Jeong Y; Yang Y; Kwon J; Lee KH; Han HS
Cancer Res Treat; 2018 Jul; 50(3):908-916. PubMed ID: 28934846
[TBL] [Abstract][Full Text] [Related]
14. Primary tumour resection showed survival benefits for non-small-cell lung cancers with unexpected malignant pleural dissemination.
Ren YJ; She YL; Dai CY; Jiang GN; Fei K; Chen C
Interact Cardiovasc Thorac Surg; 2016 Mar; 22(3):321-6. PubMed ID: 26705302
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis.
Yoshimura A; Yamada T; Tsuji T; Hamashima R; Shiotsu S; Yuba T; Takumi C; Uchino J; Hiraoka N; Takayama K
Thorac Cancer; 2019 Mar; 10(3):557-563. PubMed ID: 30672656
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
17. Primary tumour resection in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): a population-based study.
Li H; Sun Z; Yang F; Sui X; Liu T; Wang J
Eur J Cardiothorac Surg; 2019 Jun; 55(6):1121-1129. PubMed ID: 30726889
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
[TBL] [Abstract][Full Text] [Related]
19. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
[TBL] [Abstract][Full Text] [Related]
20. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
Kobayashi K; Soejima K; Fukunaga K; Shintani Y; Sekine I; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Takahashi K; Yamamoto N; Takiguchi Y; Miyaoka E; Okumura M; Yoshino I;
Lung Cancer; 2020 Aug; 146():236-243. PubMed ID: 32590236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
